Speciation of Antimony in Injectable Leishmanicidal Drugs by Lowering Citric Acid Concentration Used in Hydride Generation Atomic Absorption Spectrometry Analysis

Henrique J. F. Fabrino,* Cynthia P. Demicheli,* Frédéric J. G. Frezard# and Letícia M. Costa* *,

Departamento de Química, Instituto de Ciências Exatas, Universidade Federal de Minas Gerais,
Avenida Antônio Carlos, 6627, Pampulha, 31270-901 Belo Horizonte-MG, Brazil

Departamento de Fisiologia e Biofísica, Universidade Federal de Minas Gerais,
Av. Antônio Carlos, 6627, Pampulha, 31270-901 Belo Horizonte-MG, Brazil

This study proposes a procedure for speciation of antimony by hydride generation atomic absorption spectrometry in pentavalent antimony drugs. The Sb\textsuperscript{III} content was determined by selective generation of SbH\textsubscript{3} in medium with higher Sb\textsuperscript{V} concentration using 4 to 20-fold lower citric acid solutions than recommended in the available literature. The multivariate optimization of the methods was performed through factorial design followed by a central composite design (CCD). The limit of detection (LOD) and limit of quantification (LOQ) were calculated at 0.15 and 0.05 µg L\textsuperscript{-1} and 0.48 and 0.17 µg L\textsuperscript{-1}, for total Sb and Sb\textsuperscript{III}, respectively. The relative standard deviation (RSD) values ranged from 3.1 to 19.6% and 9.1 to 20.1%, while recovery ranged from 95.6 to 102.3% and 89.1 to 108.1%, for total Sb and Sb\textsuperscript{III}, respectively. This method was applied for the analysis of meglumine antimoniate samples. Total Sb and Sb\textsuperscript{III} concentrations ranged from 79.2 to 101.1 mg mL\textsuperscript{-1} and 0.08 to 0.41 mg mL\textsuperscript{-1}, respectively.

Keywords: antimony speciation, leishmaniosis, meglumine antimoniate, citric acid, multivariate optimization

Introduction

In the group of neglected infectious diseases, leishmaniasis presents itself as a major challenge, accounting for a yearly estimated 700,000-1,000,000 new cases and 26,000-65,000 deaths in the world.\textsuperscript{1} It is caused by leishmania protozoa, transmitted by the bite of infected female phlebotomine sandflies, and largely manifested as cutaneous (CL), mucocutaneous (MCL) and visceral (VL) leishmaniasis. The latter alone displays a mortality rate of non-treatable patients around 95%.\textsuperscript{1}

The first successful Brazilian treatment for cutaneous leishmaniasis was reported by Gaspar Vianna.\textsuperscript{2-6} His treatment employed intravenous injections of trivalent Sb,\textsuperscript{2-6} which were substituted a few years later by less toxic pentavalent antimony complexes as stibamine urea, the first of several safer pentavalent antimonials which remained the basis for all leishmaniasis treatments.\textsuperscript{4,5} Two of these complexes, the antimony sodium gluconate and meglumine antimoniate (MA), were exploited since the 1940s and are still the most widely used drugs.\textsuperscript{1,6}

Nevertheless, antimonial therapy often requires close medical supervision, demanding parenteral injections for local pain and causing systemic side effects such as nausea, vomiting, weakness, myalgia, abdominal cramps, diarrhea, rash, hepatotoxicity and cardiotoxicity.\textsuperscript{5,7} Generally, antimony drugs should be administered parenterally daily (typically 20 mg Sb kg\textsuperscript{-1} per day for 20-30 days, not exceeding 850 mg of Sb),\textsuperscript{4,6} but their toxicity mechanisms remain undiscovered. Even so, for pentavalent antimonials, Sb\textsuperscript{III} present as residues or produced through tissue reduction\textsuperscript{8-12} is widely accepted as the responsible for side effects, antileishmanial action and drug resistance.\textsuperscript{6,13} In fact, studies of the cytotoxicity mechanism of the emetic tartar suggest that Sb\textsuperscript{III} not only depletes intracellular glutathione and inhibits glutathione reductase, compromising the thiol homeostasis,\textsuperscript{12,14,15} but also increases oxidative stress and reactive oxygen species (ROS), leading to apoptosis.\textsuperscript{12,15-17}

Meglumine antimoniate (MA) may be synthesized from K\textsubscript{2}Sb(OH)\textsubscript{6} or SbCl\textsubscript{5}\textsubscript{1} through two different synthetic
routes which furnish compounds with lower in vitro cytotoxicity or even no significant histological changes or increased apoptotic activity in rats when compared to commercial MA. Considering that MA efficacy is related to the concentration of SbV and its toxicity may be related to the presence of SbIII as a contaminant, it is important to determine the concentration of these two species as minimum quality parameters for drugs used in leishmaniasis treatment.

Hydride generation (HG) associated with atomic absorption spectrometry is a powerful tool for total Sb and SbIII speciation at concentrations in the µg L⁻¹ range, as well as hydride generation-inductively coupled plasma optical emission spectrometry (HG-ICP OES). Inorganic antimony speciation usually occurs in two steps: first, a sample portion is used to determine total antimony in which the SbV is reduced to the SbIII oxidation state using a reducing agent, such as L-cysteine, thiourea, potassium iodide and potassium bromide. Subsequently, another portion of the sample is subjected to SbIII determination in the presence of citrate, which forms a strong complex with SbV but does not react with SbIII. However, the use of citric acid may contribute to the memory effect, requiring a blank reading at each SbIII determination, as well as causing severe contamination of the inner wall of the T quartz cell, requiring periodic cleaning by immersion in a nitric acid/hydrofluoric solution to maintain sensitivity.

The goal of this work was to develop a simple and fast procedure applied to inorganic antimony speciation in MA drugs used in the treatment of leishmaniasis, which consisted of the development of two HG-AAS analysis methods: total antimony using a reducing agent; and antimony(III) in the presence of citrate. The procedures were optimized by resorting to a full factorial design and central composite design (CCD). Multivariate strategy allows the mapping of the experimental domain using a smaller number of experiments compared to a univariate methodology. Understanding the main factors and their interactions permitted the development of a mathematical model to predict instrumental response.

**Experimental**

**Instrumentation**

A SpectrAA-240 flame atomic absorption spectrometer (FAAS) (Agilent Technologies, Santa Clara, USA) equipped with a VGA-77 continuous flow hydride generator accessory was used. FAAS operating conditions were: wavelength, 217.6 nm; spectral resolution, 0.5 nm; lamp current, 7 mA; and acetylene and air flow rates, 2.1 and 13.5 L min⁻¹, respectively. High purity argon was used as purge gas at a flow rate of 90 mL min⁻¹. A quartz tube cell was heated under the flame and used for Sb atomization. A sketch of the HG system is shown in Figure 1. The multivariate optimization process was performed using Statistica version 10.

**Reagents and solutions**

In the preparation of aqueous solutions, ultrapure water was used, obtained with a Direct-Q 3 system (Millipore, Burlington, USA) with resistivity of 18.2 MΩ cm. All materials, glassware and sample containers used throughout this work were previously cleaned in 10% (v v⁻¹) nitric acid solution (Merck, Rio de Janeiro, Brazil), immersed in acid bath for 16 h, rinsed with deionized water and dried in a dust free environment. A stock solution containing 1000 mg L⁻¹ SbV was prepared by dissolving 0.1091 g of KSb(OH)₆ (Sigma-Aldrich, St. Louis, USA) in 50.0 mL of 5% (m v⁻¹) HCl (Sigma-Aldrich, St. Louis, USA), and a standard stock solution containing 500 mg L⁻¹ SbIII was prepared by dissolving 0.1385 g of K₂(C₄H₂O₆Sb)₂.3H₂O (Neon Comercial Ltda, São Paulo, Brazil) in 50.0 mL of 0.05 mol L⁻¹ citric acid (Neon Comercial Ltda, São Paulo, Brazil). Intermediate standards were prepared daily by diluting aliquots of the stock solution with ultra-pure water. The tetrahydroborate solution was prepared daily by dissolving solid NaBH₄ (Vetec Quimica Fina Ltda, Rio de Janeiro, Brazil) and NaOH (Isofar Ltda, Capivari, Brazil) in water. A mixture of HCl (Sigma-Aldrich, St. Louis, USA), KI (Êxodo Científica, Sumaré, Brazil) and ascorbic acid (Carlo Erba Reagents, Vexin, France) were used as working solutions for total Sb determination, and citric acid (Neon Comercial Ltda, São Paulo, Brazil) was used to prepare the working solution for SbV determination.
Samples

Three commercial MA samples (CMA1-CMA3) from different lots and four synthetic MA samples (SMA1-SMA-4), synthesized using the procedure described by Demicheli et al.,\textsuperscript{18} were used in this work. The SMA1 and SMA2 formulations were prepared using SbCl\textsubscript{5} as a pentavalent antimony source, while SMA3 and SMA4 samples were synthesized using KSb(OH)\textsubscript{6}. Commercial and synthetic samples had a nominal concentration of 81 and 87 mg mL\textsuperscript{-1} of Sb\textsuperscript{V} in aqueous solution, respectively. Samples were diluted with water and working solutions were prepared daily before use. The dilution factor used were 22,500,000 for Sb total and 275,000 for Sb\textsuperscript{III}. Total Sb and Sb\textsuperscript{III} determinations of samples were performed under optimized conditions.

Procedure

In the screening stage, factorial design was made based on some studies in the literature,\textsuperscript{20,21} and on the conditions recommended by the equipment manufacturer. Central composite design (CCD) is a response surface methodology (RSM) used to find optimal conditions of the factors or variables. Analysis of variance (ANOVA) at 0.05 significance level was employed to identify significant factors and interaction effects. The validation of the models was determined by comparing the variance of the lack of fit (lof) and the pure experimental error (pe) with the values of the Fisher distribution ($F$-test, $p = 0.05$).\textsuperscript{24,25} Experiments were conducted in randomized order.

For total Sb determination, all species of Sb\textsuperscript{V} shall be converted to Sb\textsuperscript{III} by the addition of an analytical standard (or MA sample) aliquot to a working solution containing 1.0 mol L\textsuperscript{-1} HCl and a reducing agent (L-cysteine, KBr, thiourea and KI were previously tested). Potassium iodide was the reducing agent selected in the experimental design. It allows better instrumental responses, and ascorbic acid was added to stabilize the working solution. Hydrochloric acid and a mixture of NaBH\textsubscript{4} and NaOH was used in the acid channel and in the reducer channel of the VGA-77 accessory (Figure 1). To evaluate the signal intensity in the method optimization, working solutions were fortified with 5.0 µg L\textsuperscript{-1} Sb\textsuperscript{V}.

For the selective determination of Sb\textsuperscript{III}, an analytical standard (or MA sample) aliquot should be added to a working solution containing citric acid that forms a stable complex with the present Sb\textsuperscript{V} and does not allow it to form hydrides and interfere with the Sb\textsuperscript{III} signal. Citric acid also is responsible for reacting with borohydride to provide hydrogen for the stibin formation reaction (SbH\textsubscript{3}). Therefore, it was used in the acid channel at the same concentration as the working solution while a mixture of NaBH\textsubscript{4} and NaOH was used in the reducing channel of the VGA-77 accessory (Figure 1). To evaluate the selective determination of Sb\textsuperscript{III} and to verify the occurrence of signals related to Sb\textsuperscript{V}, in each trial of the experimental designs two working solutions were analyzed, one containing 5.0 µg L\textsuperscript{-1} Sb\textsuperscript{III} and the other with a mixture of 5.0 µg L\textsuperscript{-1} Sb\textsuperscript{III} and 400.0 µg L\textsuperscript{-1} Sb\textsuperscript{V}.

Results and Discussion

Optimization of the total Sb determination method

Initially, a $2^4$ full factorial design with center point (CP) were evaluated: KI concentration [1.0(−); 5.5(0) and 10.0(+), in percentage (m v\textsuperscript{-1})]; NaBH\textsubscript{4} concentration [0.6(−); 1.3(0) and 2.0(+), in percentage (m v\textsuperscript{-1})]; HCl concentration used in the acid channel [5.0(−); 7.5(0) and 10.0(+), mol L\textsuperscript{-1}], and the contact time of the analyte with the working solution (0(−); 60(0) and 120(+), s). Pareto’s chart (Figure 2) shows that the variables [NaBH\textsubscript{4}], [KI] and contact time had a significant effect on instrumental response at 95% confidence level. The negative sign of the effects denotes that the use of lower NaBH\textsubscript{4} and KI concentrations led to an increase of the instrumental response, and the positive sign shows an increase in the response using the contact time ($p = 0.05$).

A matrix experiments of central composite design (CCD) (Table 1) was performed to evaluate the previously selected significant factors (HCl concentration was set at 5.0 mol L\textsuperscript{-1}). The optimal values obtained by deriving the mathematical equations 1, 2 and 3 obtained by this
Speciation of Antimony in Injectable Leishmanicidal Drugs by Lowering Citric Acid Concentration

J. Braz. Chem. Soc.

Optimization of the Sb\textsuperscript{III} determination method

To optimize the analytical conditions for Sb\textsuperscript{III} determination by HG-AAS, three factors were initially evaluated using a 2\textsuperscript{3} factorial design with CP (Table 2): concentration of citric acid used in the working solution and in the acid channel; NaBH\textsubscript{4} concentration and analyte contact time with the working solution. During the experiments, the T quartz cell capillary became clogged due to the use of high citric acid concentrations in some assays. Therefore, it was necessary to interrupt the quantification to clean the T quartz cell by immersion in nitric/hydrofluoric acid solution for 30 s. This indicates that high concentration of citric acid should be avoided, to increase lifetime of the T cell. The Pareto’s chart (Figure 3) shows that the variables [NaBH\textsubscript{4}] and [citric acid] had a significant effect on instrumental response at 95% confidence level. The signs of effects indicated that increasing NaBH\textsubscript{4} concentration and decreasing citric acid concentration affected the instrumental response (\(p = 0.05\)).

Table 1. Matrix experiments of central composite design (CCD) for total Sb determination by HG-AAS; values in parentheses are the coded values

| Assay | [KI] / (\(\%\, m\, v^{-1}\)) | [NaBH\textsubscript{4}] / (\(\%\, m\, v^{-1}\)) | time / s | Integrated absorbance |
|-------|-------------------------------|---------------------------------|----------|----------------------|
| 1     | 0.8(\(-1\))                   | 0.7(\(-1\))                     | 25(\(-1\)) | 0.1916               |
| 2     | 0.8(\(-1\))                   | 0.7(\(-1\))                     | 95(\(+1\)) | 0.1728               |
| 3     | 0.8(\(-1\))                   | 1.1(\(+1\))                     | 25(\(-1\)) | 0.2385               |
| 4     | 0.8(\(-1\))                   | 1.1(\(+1\))                     | 95(\(+1\)) | 0.1601               |
| 5     | 1.6(\(+1\))                   | 0.7(\(-1\))                     | 25(\(-1\)) | 0.2036               |
| 6     | 1.6(\(+1\))                   | 0.7(\(-1\))                     | 95(\(+1\)) | 0.1788               |
| 7     | 1.6(\(+1\))                   | 1.1(\(+1\))                     | 25(\(-1\)) | 0.1916               |
| 8     | 1.6(\(+1\))                   | 1.1(\(+1\))                     | 95(\(+1\)) | 0.1418               |
| 9     | 0.5(\(-\alpha\))              | 0.9(0)                           | 60(0)     | 0.1973               |
| 10    | 1.9(\(+\alpha\))              | 0.9(0)                           | 60(0)     | 0.1675               |
| 11    | 1.2(0)                         | 0.6(\(-\alpha\))                | 60(0)     | 0.2107               |
| 12    | 1.2(0)                         | 1.2(\(+\alpha\))                | 60(0)     | 0.1678               |
| 13    | 1.2(0)                         | 0.9(0)                           | 0(\(-\alpha\)) | 0.1944   |
| 14    | 1.2(0)                         | 0.9(0)                           | 120(\(+\alpha\)) | 0.2002 |
| CP    | 1.2(0)                         | 0.9(0)                           | 60(0)     | 0.1953               |
| CP    | 1.2(0)                         | 0.9(0)                           | 60(0)     | 0.1929               |
| CP    | 1.2(0)                         | 0.9(0)                           | 60(0)     | 0.2043               |
| CP    | 1.2(0)                         | 0.9(0)                           | 60(0)     | 0.2064               |
| CP    | 1.2(0)                         | 0.9(0)                           | 60(0)     | 0.1825               |

CP: central point; \(\alpha = 1.682\).

Table 2. Matrix experiments of factorial design 2\textsuperscript{3} with CP for Sb\textsuperscript{III} determination by HG-AAS; values in parentheses are the coded values

| Assay | [CA] / (\(\%\, m\, v^{-1}\)) | [NaBH\textsubscript{4}] / (\(\%\, m\, v^{-1}\)) | time / s | IA\textsuperscript{a} | IA\textsuperscript{b} |
|-------|-------------------------------|---------------------------------|----------|----------------------|----------------------|
| 1     | 4(\(-\))                      | 0.6(\(-\))                     | 0(\(-\)) | 0.1854               | 0.1812               |
| 2     | 20(\(+\))                     | 0.6(\(-\))                     | 0(\(-\)) | 0.0979               | 0.1043               |
| 3     | 4(\(-\))                      | 2.0(\(+\))                     | 0(\(-\)) | 0.1846               | 0.1921               |
| 4     | 20(\(+\))                     | 2.0(\(+\))                     | 0(\(-\)) | 0.2315               | 0.1633               |
| 5     | 4(\(-\))                      | 0.6(\(+\))                     | 120(\(+\)) | 0.1870 | 0.1881               |
| 6     | 20(\(+\))                     | 0.6(\(+\))                     | 120(\(+\)) | 0.1222 | 0.1286               |
| 7     | 4(\(-\))                      | 2.0(\(+\))                     | 120(\(+\)) | 0.1837 | 0.1885               |
| 8     | 20(\(+\))                     | 2.0(\(+\))                     | 120(\(+\)) | 0.1753 | 0.1791               |
| CP    | 12(0)                         | 1.3(0)                          | 60(0)     | 0.1779               | 0.2103               |
| CP    | 12(0)                         | 1.3(0)                          | 60(0)     | 0.1777               | 0.1637               |
| CP    | 12(0)                         | 1.3(0)                          | 60(0)     | 0.1872               | 0.2030               |
| CP    | 12(0)                         | 1.3(0)                          | 60(0)     | 0.1955               | 0.2018               |
| CP    | 12(0)                         | 1.3(0)                          | 60(0)     | 0.1826               | 0.2023               |

\textsuperscript{a}Citric acid concentration; \textsuperscript{b}integrated absorbance in presence of 5 \(\mu\)g L\textsuperscript{-1} of Sb\textsuperscript{III}; \textsuperscript{c}integrated absorbance in presence of 5 \(\mu\)g L\textsuperscript{-1} of Sb\textsuperscript{III} and 400 \(\mu\)g L\textsuperscript{-1} of Sb\textsuperscript{V}. CP: central point.

Figure 3. Pareto’s chart obtained from factorial design 2\textsuperscript{3} with CP for Sb\textsuperscript{III} determination by HG-AAS.

On the other hand, the interaction between these two factors had a positive effect on the response. Therefore, increasing the concentration of one reagent while
decreasing the concentration of the other will negatively impact the instrumental response. The variation of contact time was not significant, but its interaction with the reduced concentration led to a negative effect on the instrumental response. Based on this assessment, the CCD developed were shown in Table 3.

It took at least 100 s of contact time to suppress the interference from Sb V when low concentrations of citric acid were applied, so this time was used in all subsequent experiments. As can be seen in Figure 4a, the response surface showed two trends, so in a second CCD (Table 3) we chose to explore the region in which lower concentrations of reagents were used. The response surface obtained in Figure 4b shows a maximum absorbance point for coordinates 1.2% (m v⁻¹) and 1.5% (m v⁻¹), referring to the NaBH₄ and citric acid concentration values, respectively. However, the model presented a lack of fit, so we decided to perform a third CCD experiment with the optimal concentration values obtained at the central point (Table 3). The model indicated a trend of higher sensitivity in two different directions again (Figure 4c), so following the same reasoning, we chose to explore the region of lowest reagent concentration values in a fourth CCD experiment (Table 3). The analysis of the response surface obtained (Figure 4d) showed that the highest absorbance values were obtained in the intermediate regions, especially at the point with concentration values of 1.0% (m v⁻¹) and 0.8% (m v⁻¹) for citric acid and NaBH₄, respectively, selected for the optimization.

**Table 3.** Matrix experiments of central composite design (CCD) for SbIII determination by HG-AAS

| Assay | [Citric acid] / (%, m v⁻¹) | [NaBH₄] / (%, m v⁻¹) | Integrated absorbance a | Integrated absorbance b |
|-------|--------------------------|---------------------|------------------------|------------------------|
|       | 1st | 2nd | 3rd | 4th | 1st | 2nd | 3rd | 4th |                |                |
| 1     | 2.0 | 1.0 | 1.0 | 0.6 | 3.0 | 2.0 | 1.6 | 1.0 | 0.2425 | 0.2479 |
| 2     | 6.0 | 4.0 | 2.0 | 1.0 | 3.0 | 2.0 | 1.6 | 1.0 | 0.2240 | 0.2325 |
| 3     | 2.0 | 1.0 | 1.0 | 0.6 | 1.0 | 1.0 | 1.0 | 0.8 | 0.2436 | 0.2632 |
| 4     | 6.0 | 4.0 | 2.0 | 1.0 | 1.0 | 1.0 | 1.0 | 0.8 | 0.2462 | 0.2513 |
| 5     | 1.2 | 0.4 | 0.8 | 0.5 | 2.0 | 1.5 | 1.3 | 0.9 | 0.2351 | 0.2726 |
| 6     | 4.0 | 2.5 | 1.5 | 0.8 | 3.4 | 2.2 | 1.7 | 1.1 | 0.2426 | 0.2676 |
| 7     | 6.8 | 4.6 | 2.2 | 1.1 | 2.0 | 1.5 | 1.3 | 0.9 | 0.2458 | 0.2591 |
| 8     | 4.0 | 2.5 | 1.5 | 0.8 | 0.6 | 0.8 | 0.9 | 0.7 | 0.2443 | 0.2573 |
| CP    |     |     |     |     | 2.0 | 1.5 | 1.3 | 0.9 | 0.2452 | 0.2666 |
| CP    | 4.0 | 2.5 | 1.5 | 0.8 | 2.0 | 1.5 | 1.3 | 0.9 | 0.2692 | 0.2749 |
| CP    | 4.0 | 2.5 | 1.5 | 0.8 | 2.0 | 1.5 | 1.3 | 0.9 | 0.2519 | 0.2684 |
| CP    | 4.0 | 2.5 | 1.5 | 0.8 | 2.0 | 1.5 | 1.3 | 0.9 | 0.2504 | 0.2624 |
| CP    | 4.0 | 2.5 | 1.5 | 0.8 | 2.0 | 1.5 | 1.3 | 0.9 | 0.2452 | 0.2666 |

aIntegrated absorbance of 4th CCD in the presence of 5 µg L⁻¹ SbIII; bintegrated absorbance of 4th CCD in the presence of 5 µg L⁻¹ SbIII and 400 µg L⁻¹ SbV.

**Interference study**

The working solutions containing the analytes and potentially interfering ions were analyzed by applying the optimized methods. Previous analysis of some commercial MA samples showed the presence of As, Cu and Pb as contaminants. Although small amounts of nickel were detected (< 0.3 mg L⁻¹) in undiluted commercial samples, this element was also included in the interference study due to its strong effect on Sb measurements by HG-AAS. The selectivity of the methods was evaluated by preparing working solutions contaminated with 3.5 µg L⁻¹ SbV or 1.5 µg L⁻¹ SbIII for total Sb and SbIII determination methods, respectively. Another group of working solutions containing the same amounts of SbV or SbIII were also contaminated with 20 µg L⁻¹ of interfering NiII, PbII, CuII or AsIII, as well as 400 µg L⁻¹ of SbV for the SbIII determination method. Each of the solutions with or without interfering elements was prepared in independent triplicates, and the results were compared using 95% confidence level hypothesis tests (F-test and t-test). No interference was observed in Sb signals at the studied concentrations. Using 1.0% (m v⁻¹) citric acid, it was possible to selectively detect SbIII in the presence of 8,000-fold SbV, while Flores et al. observed this selective detection in the presence of 947-fold SbV using 20% (m v⁻¹) citric acid, and selective quantification of SbIII was possible in the presence of 2,350-fold SbV, while the authors obtained this selective quantification in the presence of 1,300-fold SbV using 4% (m v⁻¹) citric acid.
Validation of the proposed method

In order to demonstrate that the analytical method produced reliable results and is suitable for the intended purpose, we subjected the optimized method to systematic evaluation by the experimental tests for validation indicated by the main guide used in Brazil. 28

Linearity was verified according to the procedures proposed by de Souza and Junqueira. 29 To estimate the linear regression parameters, the ordinary least squares (OLS) method was used. Six equally spaced points (to avoid leverage points) were used to plot the analytical curves, and readings were taken randomly. The concentration ranges chosen for evaluation of the calibration curves linearity were 0.0 to 8.0 µg L⁻¹ and 0.0 to 3.7 µg L⁻¹ for the total Sb and SbIII determination methods, respectively. The Jackknife test was performed to detect and remove outliers. The verification that regression residuals were normally distributed, independent and homoscedastic was confirmed by the Ryan-Joiner coefficients of 0.9856 and 0.9787, Durbin-Watson statistics of 1.67 and 1.56, and t-Levene statistics of 0.166 and 0.223 for the total Sb and SbIII determination methods, respectively. The linearity of the model was confirmed by ANOVA, which revealed that the regression was significant while the lack of fit was not significant. All statistical tests were performed with a 95% confidence level (p = 0.05).

The limits of detection (LOD) and quantification (LOQ) were calculated by measuring seven independently prepared blank analytical solutions (working solutions without metal). The LODs were calculated at 0.15 and 0.05 µg L⁻¹, and the LOQs were measured at 0.48 and 0.17 µg L⁻¹ for total Sb and SbIII, respectively (LOD = LOQ/3.3 and LOQ = 10s/b, where s is the standard deviation of responses from 7 independent blanks and b is the slope of the analytical curve).

Figure 4. Response surface plots obtained from CCDs for SbIII. (a) 1st CCD; (b) 2nd CCD; (c) 3rd CCD and (d) 4th CCD.
For repeatability and recovery tests, the sample was fortified at three concentration levels: 0.5; 3.5 and 8.0 µg L\(^{-1}\) for Sb total, and 0.2; 1.5 and 3.5 µg L\(^{-1}\) for Sb\(^{III}\), performing seven independent determinations per level, expressed as the relative standard deviation (RSD) and percentage respectively. The RSD values ranged from 3.1 to 19.6% and 9.1 to 20.1%, while recovery ranged from 95.6 to 102.3% and 89.1 to 108.1%, for total Sb and Sb\(^{III}\) respectively. These values meet the acceptance criteria suggested by the Association of Official Analytical Chemists (AOAC) for the evaluated concentration ranges, which indicates the repeatability limit of 30% for the RSD value and the range of 40 to 120% for the recovery. Validation results are presented in Table 4.

Table 4. Analytical figures of merit for total Sb and Sb\(^{III}\) determinations by HG-AAS

| Parameter                              | Value (total Sb) | Value (Sb\(^{III}\)) |
|----------------------------------------|------------------|----------------------|
| Linear range / (µg L\(^{-1}\))         | 0-8.00           | 0-3.70               |
| Slope                                  | 0.0369           | 0.0602               |
| Intersection                           | 0.0065           | 0.0009               |
| \(R^2\) (n = 3)                        | 0.9959           | 0.9968               |
| LOD (n = 7) / (µg L\(^{-1}\))          | 0.15             | 0.05                 |
| LOQ (n = 7) / (µg L\(^{-1}\))          | 0.48             | 0.17                 |
| Repeatability by levels (n = 7) / %RSD |                  |                      |
| low                                    | 19.6             | 20.1                 |
| middle                                 | 7.3              | 10.1                 |
| high                                   | 3.1              | 9.1                  |
| Recovery by levels (n = 7) / %          |                  |                      |
| low                                    | 95.6             | 108.1                |
| middle                                 | 102.3            | 94.5                 |
| high                                   | 96.5             | 89.1                 |

\(R^2\): coefficient of determination; n: number of independent replicates; LOD: limit of detection; LOQ: limit of quantification; RSD: relative standard deviation.

Table 5. Concentration of Sb\(^{III}\) and total Sb in commercial and synthetic samples using the HG-AAS proposed procedure. Results are expressed as mean ± standard deviation (n = 3); values in parentheses are the percentages of Sb\(^{III}\) out of total Sb

| Sample | Total Sb / (mg mL\(^{-1}\)) | Sb\(^{III}\) / (mg mL\(^{-1}\)) |
|--------|-----------------------------|--------------------------------|
| CMA1   | 83.37 ± 1.89                | 0.14 ± 0.01 (0.17)            |
| CMA2   | 80.08 ± 1.31                | 0.17 ± 0.01 (0.21)            |
| CMA3   | 101.1 ± 2.9                 | 0.08 ± 0.04 (0.08)            |
| SMA1   | 79.23 ± 4.16                | 0.41 ± 0.01 (0.52)            |
| SMA2   | 82.35 ± 1.96                | 0.41 ± 0.28 (0.50)            |
| SMA3   | 83.59 ± 2.80                | 0.11 ± 0.01 (0.14)            |
| SMA4   | 82.13 ± 2.16                | 0.13 ± 0.02 (0.16)            |

Determination of total Sb and Sb\(^{III}\) in commercial and synthetic meglumine antimoniate samples

Total Sb and Sb\(^{III}\) were determined in commercial and synthetic MA samples using optimized conditions (Table 5). Total Sb concentration in three commercial MA samples lots ranged from 80.1 to 101.1 mg mL\(^{-1}\) (nominal value of 81 mg mL\(^{-1}\)). In the determination of trivalent Sb in commercial MA samples, the results ranged from 0.08 to 0.17 mg mL\(^{-1}\), which corresponds to percentages of 0.08 to 0.21% of total Sb in commercial drugs. These results are equivalent to others found in the literature reporting Sb\(^{III}\) concentrations less than 0.3 mg mL\(^{-1}\). In earlier publications, Sb\(^{III}\) levels in commercial MA ranging from 1.7 to 15.5 mg mL\(^{-1}\) were reported, suggesting an adaptation in the commercial MA manufacturing process to control pentavalent antimony reduction.

Table 5. Concentration of Sb\(^{III}\) and total Sb in commercial and synthetic samples using the HG-AAS proposed procedure. Results are expressed as mean ± standard deviation (n = 3); values in parentheses are the percentages of Sb\(^{III}\) out of total Sb

Four MA formulations were synthesized for this work based on the method described by Demicheli et al. The SMA1 and SMA2 formulations were prepared using SbCl\(_5\) as a pentavalent antimony source, while SMA3 and SMA4 samples were synthesized using KSb(OH)\(_6\). There was no significant difference between the amounts of total Sb found in the four formulations, which were very close to the theoretical value, while the reported Sb\(^{III}\) content was slightly higher in formulations prepared with SbCl\(_5\).

Results in Table 5 indicated that these formulations are suitable in the treatment of leishmaniasis with an adequate amount of Sb\(^{V}\) and a low content of Sb\(^{III}\). It should be suggested as an efficient treatment against the disease with low potential of side effects. However, more studies are necessary to support this idea.

Conclusions

A method for inorganic antimony speciation in meglumine antimoniate samples used in the treatment of leishmaniasis was developed and evaluated.

In the development of the analytical method, the use of multivariate optimization allowed us to reach the condition of higher analytical signal intensity with a reduced number of assays, besides providing information on the interaction between the evaluated variables, which in the Sb\(^{III}\) determination method development was crucial to find the optimal condition of analysis with the use of a lower citric acid concentration. The use of citric acid at lower concentrations has eliminated problems reported in some publications such as the need for periodic quartz cell cleaning to maintain sensitivity and the requirement to measure a blank analytical solution after each Sb determination to
correct memory effects. Thus, there was no loss in the analytical frequency by one sample per min (45 s of delay and 15 s of triplicate reading). Even at lower concentrations, citric acid retained the ability to suppress SbV signals present at approximately 2,000-fold higher concentrations than SbIII.

The methods were able to quantify total Sb and SbIII in commercial and synthetic meglumine antimoniate samples, and may be used in the quality control of these formulations.

Acknowledgments

We are grateful for the financial support and scholarships from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).

References

1. https://www.who.int/en/news-room/fact-sheets/detail/novel-leishmaniasis, accessed in July 2020.
2. Berman, J. D.; Rev. Infect. Dis. 1988, 10, 569.
3. Sneader, W.; Drug Discovery: A History, vol. 1, 1st ed.; John Wiley & Sons Ltd: Chichester, UK, 2005, p. 472.
4. Rath, S.; Frézard, F.; Demicheli, C.; Ribeiro, R.; Rodrigues, C.; Villardi, M.; Castro, H. C.; Santos, T. C.; Molecules 2009, 14, 2317.
5. Lawn, S. D.; Armstrong, M.; Whitty, C. J.; Trans. R. Soc. Trop. Med. Hyg. 2006, 100, 264.
6. Goyard, S.; Coste, J.; Gordon, J.; Showalter, M.; Duncan, R.; Turco, S. J.; Beverley, S. M.; Mol. Biochem. Parasitol. 2003, 130, 31.
7. Burguera, J. L.; Burguera, M.; Petit de Peña, Y.; Lugo, A.; Anez, N.; Trace Elem. Med. 1993, 10, 66.
8. Lugo de Yarbuh, A.; Anez, N.; Petit de Peña, Y.; Burguera, J. L.; Burguera, M.; Ann. Trop. Med. Parasitol. 1994, 88, 37.
9. Marquis, N.; Gourbal, B.; Rosen, B. P.; Mukhopadhyay, R.; Ouellette, M.; Mol. Microbiol. 2005, 57, 1690.
10. Ponte-Sucre, A.; Gamarro, F.; Dujardin, J. C.; Barrett, M. P.; López-Vélez, R.; García-Hernández, R.; Pountain, A. W.; Mwenechanya, R.; Papadopoulou, B.; PLoS Neglected Trop. Dis. 2017, 11, e0006052.
11. Kato, K. C.; Morais-Teixeira, E.; Reis, P. G.; Silva-Bracellos, N. M.; Salain, P.; Campos, P. P.; Corrêa-Junior, J. D.; Rabello, A.; Demicheli, C.; Frézard, F.; Antimicrob. Agents Chemother 2014, 58, 481.
12. Wyllie, S.; Cunningham, M. L.; Fairlamb, A. H.; J. Biol. Chem. 2004, 279, 39925.
13. Wyllie, S.; Fairlamb, A. H.; Biochem. Pharmacol. 2006, 71, 257.
14. Timerstein, M. A.; Plews, P. I.; Walker, C. V.; Woolery, M. D.; Wey, H. E.; Torason, M. A.; Toxicol. Appl. Pharmacol. 1995, 130, 41.
15. Pulido, M. D.; Parrish, A. R.; Mutat. Res. 2003, 533, 227.
16. Demicheli, C.; Ochoa, R.; Lulu, I. S.; Gozzo, F. C.; Eberlin, M. N.; Frézard, F.; Appl. Organomet. Chem. 2007, 17, 226.
17. Dzamitika, S. A.; Falcão, C. A. B.; Oliveira, F. B.; Marbeuf, C.; Garnier-Suillerot, A.; Demicheli, C.; Rossi-Bergmann, B.; Frézard, F.; Chem. Biol. Interact. 2006, 160, 217.
18. Demicheli, C.; Ochoa, R.; Lulu, I. S.; Gozzo, F. C.; Eberlin, M. N.; Frézard, F.; Appl. Organomet. Chem. 2003, 17, 226.
19. Wyllie, S.; Fairlamb, A. H.; Biochem. Pharmacol. 2006, 71, 257.
20. Timerstein, M. A.; Plews, P. I.; Walker, C. V.; Woolery, M. D.; Wey, H. E.; Torason, M. A.; Toxicol. Appl. Pharmacol. 1995, 130, 41.
21. Pulido, M. D.; Parrish, A. R.; Mutat. Res. 2003, 533, 227.
22. Demicheli, C.; Ochoa, R.; Lulu, I. S.; Gozzo, F. C.; Eberlin, M. N.; Frézard, F.; Appl. Organomet. Chem. 2007, 17, 226.
23. Dzamitika, S. A.; Falcão, C. A. B.; Oliveira, F. B.; Marbeuf, C.; Garnier-Suillerot, A.; Demicheli, C.; Rossi-Bergmann, B.; Frézard, F.; Chem. Biol. Interact. 2006, 160, 217.
24. Flores, E. M. M.; Santos, E. P.; Barin, J. S.; Zanella, R.; Dressler, V. L.; Bittencourt, C. F.; J. Anal. At. Spectrom. 2002, 17, 819.
25. Flores, E. M. M.; Paula, F. R.; Silva, E. F. B.; Moraes, D. P.; Paniz, J. N. G.; Santos, E. P.; Dressler, V. L.; Bittencourt, C. F.; At. Spectrosc. 2003, 24, 15.
26. Cabral, L. M.; Juliano, V. M. N.; Dias, L. R. S.; Dornelas, C. B.; Rodrigues, C. R.; Villardi, M.; Castro, H. C.; Santos, T. C.; Mem. Inst. Oswaldo Cruz 2008, 103, 130.
27. Ferreira, S. L. C.; dos Santos, W. N. L.; dos Santos, I. F.; Junior, M. M. S.; Silva, L. O. B.; Barbosa, U. A.; de Santana, F. A.; Queiroz, A. F. S.; Microchem. J. 2014, 114, 22.
28. Lundstedt, T.; Seifert, E.; Abram, J.; Nyström, A.; Pettersen, J.; Bergman, R.; Chemom. Intell. Lab. Syst. 1998, 32, 3.
29. Ferreira, S. L. C.; Lemos, V. A.; de Carvalho, V. S.; da Silva, E. G. P.; Queiroz, A. F. S.; Felix, C. S. A.; da Silva, D. L. F.; Dourado, G. B.; Oliveira, R. V.; Microchem. J. 2018, 140, 176.
30. Statistica, version 10; StatSoft, Inc., USA, 2010.
31. Dédina, J.; Tsalev, D. L.; Hidride Generation Atomic Absorption Spectrometry, vol. 6, 1st ed.; John Wiley & Sons Ltd: Chichester, UK, 1995.
32. Institute Nacional de Metrologia, Normalização e Qualidade Industrial (INMETRO); DOQ-CGCRE-009 Orientação sobre Validação de Métodos Analíticos, 2016. Available at http://www.inmetro.gov.br/Sidoq/Arquivos/CGCRE/DOQ/DOQ-CGCRE-008.pdf, accessed in July 2020.
33. de Souza, S. V. C.; Junqueira, R. G.; Anal. Chim. Acta 2005, 552, 25.
34. Association of Official Analytical Chemists (AOAC); Guidelines for Standard Method Performance Requirements, 2016, available at http://www.aoac.org/app_f.pdf, accessed in July 2020.
35. Santos, V. S.; Santos, W. D. R.; Kubota, L. T.; Tarley, C. R. T.; J. Pharm. Biomed. Anal. 2009, 50, 151.
36. Lukaszczyk, L.; Zyrnicki, W.; J. Pharm. Biomed. Anal. 2010, 52, 747.
37. Seby, F.; Gleyse, C.; Grosso, O.; Plaut, B.; Donard, O. F. X.; Anal. Bioanal. Chem. 2012, 404, 2939.
38. Franco, M. A.; Barbosa, A. C.; Rath, S.; Dorea, J. G.; Am. J. Trop. Med. Hyg. 1995, 52, 435.
35. Ruth, S.; Jardim, W. F.; Dorea, J. G.; *Fresenius' J. Anal. Chem.* 1997, 358, 548.
36. González, M. J.; Renedo, O. D.; Martinez, M. J.; *Talanta* 2005, 68, 67.
37. González, M. J.; Renedo, O. D.; Martinez, M. J.; *Electroanalysis* 2006, 18, 1159.
38. González, M. J.; Renedo, O. D.; Martinez, M. J.; *Talanta* 2007, 71, 691.
39. Renedo, O. D.; Martinez, M. J.; *Electrochem. Commun.* 2007, 9, 820.

Submitted: March 11, 2020
Published online: July 22, 2020

This is an open-access article distributed under the terms of the Creative Commons Attribution License.